Search
Search Constraints
You searched for: Author/Creator Liu, David M.Limit your search
- Liu, David M. [remove] 7
- 616.0757 2
- Radiology, Medical -- Canada -- Periodicals 2
- Radiology, Medical -- Periodicals 2
- 301.07205 1
- 616 1
- 616.99406 1
- 617.005 1
- 617.05 1
- A-TARE ablative transarterial radioembolization -- AE adverse event -- AFP alphafetoprotein -- BCLC Barcelona clinic liver cancer (staging) -- BCLC-A BCLC stage A, early-stage disease -- BCLC-B BCLC stage B, intermediate-stage disease -- BCLC-C BCLC stage C, advanced-stage disease -- CSPH clinically-significant portal hypertension -- cTACE conventional transarterial chemoembolization -- DEB-TACE drug-eluting bead transarterial chemoembolization -- EHS extrahepatic spread -- EBRT external beam radiation therapy -- HAE hepatic arterial embolization -- HCC hepatocellular carcinoma -- HKLC Hong Kong liver cancer (staging) -- HR hazard ratio -- HVPG hepatic venous pressure gradient -- IAT intra-arterial therapy (aka. HAT, hepatic artery-based therapy or trans-arterial therapy) -- ICI immune checkpoint inhibitor -- IRE irreversible electroporation -- LRT locoregional therapy -- LT liver transplantation -- MWA microwave ablation -- ORR overall response rate -- OS overall survival -- PFS progression-free survival -- PS performance status -- RCT randomized controlled trial -- RFA radiofrequency ablation -- SBRT stereotactic body radiation therapy -- TACE transarterial chemoembolization -- TKI tyrosine kinase inhibitor -- TTP time to progression -- TTV total tumor volume -- Y90-TARE transarterial radioembolization using the Yttrium-90 (Y90) isotope 1
- Asian expert consensus -- Hepatocellular carcinoma (HCC) -- Selective internal radiation therapy (SIRT) -- Transarterial radioembolization (TARE) -- Yttrium 90 (Y90) 1